Related Experiment Video
Updated: Dec 20, 2025

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia
Helvécio Cardoso Corrêa Póvoa1, Gabriela Ceccon Chianca1, Natalia Lopes Pontes Póvoa Iorio2
1Department of Basic Science, Universidade Federal Fluminense, Nova Friburgo, Rio de Janeiro, Brazil.
Insights
Ventilator-Associated Bacterial Pneumonia (VAP) is a significant risk for COVID-19 patients, potentially worsening outcomes and increasing hospital costs. Early prevention and treatment of VAP are crucial for improving patient recovery and survival rates.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pulmonology
Background:
- COVID-19 patients on mechanical ventilation face a heightened risk of Ventilator-Associated Bacterial Pneumonia (VAP).
- VAP in COVID-19 can lead to severe clinical deterioration, increased mortality, and prolonged hospital stays.
- The economic burden associated with extended hospitalization due to VAP is substantial.
Purpose of the Study:
- To emphasize the critical risk of VAP in hospitalized COVID-19 patients.
- To underscore the impact of VAP on clinical outcomes, mortality, and healthcare costs.
- To advocate for timely VAP prevention, detection, and treatment strategies.
Main Methods:
- Literature review and analysis of existing data on VAP in COVID-19 cohorts.
- Examination of clinical guidelines and best practices for VAP management.
- Synthesis of evidence regarding the impact of VAP on patient prognosis and resource utilization.
Main Results:
- Co-infection with VAP significantly exacerbates the clinical condition of COVID-19 patients.
- VAP is associated with a demonstrable increase in mortality rates among COVID-19 inpatients.
- Delayed VAP management correlates with longer hospitalizations and increased healthcare expenditures.
Conclusions:
- Proactive strategies for preventing, identifying, and treating VAP are essential in managing COVID-19 patients.
- Early intervention in VAP cases can significantly improve treatment success and patient outcomes.
- Addressing VAP is critical for mitigating the severity and economic impact of COVID-19.
Abstract:
This manuscript aims to highlight the risk of Ventilator-Associated Bacterial Pneumonia (VAP) in COVID-19 inpatients. The co-infection has the potential to worsen clinical condition and increase mortality in these patients, as well as to prolong and increase the costs of hospitalization. Preventing, identifying and treating early VAP can increase the chances of successful treatment in patients with COVID-19.
More Related Videos
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...

